Drug firm Orchid Pharma has received Establishment Inspection Report (EIR) from the US health regulator on the successful inspection closure for its Irungattukottai formulations plant in Tamil Nadu. The facility was inspected by the USFDA in the month of May 2015.
Establishment Inspection Report (EIR) is given to a establishment after the completion of the inspection by FDA. Orchid is present in segments such as anti-infectives, anti-inflammatory, central nervous system, cardio vascular, nutraceuticals and oral as well as sterile products.
Orchid Chemicals & Pharmaceuticals is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit (EOU).
